IRUS Total

A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer

Title: A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer
Authors: Ahmed-Salim, Y
Saso, S
Meehan, H
Galazis, N
Phelps, D
Jones, B
Chan, M
Chawla, M
Lathouras, K
Gabra, H
Fotopoulou, C
Ghaem-Maghami, S
Smith, JR
Item Type: Journal Article
Abstract: Introduction: Calcium electroporation (CaEP) is a new technique whereby intracellular concentrations of calcium are elevated by transient permeabilisation of the cell membrane using high-voltage electrical pulses. Tumour necrosis is induced with little damage to healthy tissue. Within gynaecological cancer, vulval cancer and vulval intraepithelial neoplasia (VIN) pose challenges for treatment, given the high recurrence rate, persistent symptoms and repeated resections required. In certain cases, CaEP may provide a suitable alternative. Methods: We present a case series of six patients with recurrent vulval squamous cell carcinoma(n=2), VIN III (n=2) and metastatic ovarian cancer (n=2), five of whom were treated with CaEP. This is the first known application of CaEP to gynaecological cancers .Results: The median follow-up time was 14 months (range 2-18 months). Within the cohort of patients, CaEP was applied a total of 10 times, achieving a complete response five times and partial response four times. Symptoms improved within six weeks for eight episodes following CaEP application. Beyond six weeks, symptoms eventually recurred in all patients and four patients required more than one CaEP procedure. CaEP was useful for palliation of distressing symptoms in one case of metastatic ovarian cancer. No intra-operative or post-operative complications have been reported to date. Conclusion: CaEP may be a promising short-term treatment in selected patients with recurrent VIN and vulval cancer, where other treatments had failed. If validated, it could provide an acceptable alternative where surgery is unacceptable. Long term follow-up is required to evaluate effects on recurrence.
Issue Date: 15-Aug-2021
Date of Acceptance: 12-Mar-2021
URI: http://hdl.handle.net/10044/1/88613
DOI: 10.31083/j.ejgo4204102
ISSN: 0392-2936
Publisher: Innovative Medical Press
Start Page: 662
End Page: 672
Journal / Book Title: European Journal of Gynecological Oncology
Volume: 42
Issue: 42
Copyright Statement: ©2021 The Author(s). Published by IMR Press. This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Sponsor/Funder: Cancer Research UK
Cancer Research UK
Funder's Grant Number: WSAA_P84261
Keywords: Science & Technology
Life Sciences & Biomedicine
Obstetrics & Gynecology
Ovarian cancer
Vulval cancer
1112 Oncology and Carcinogenesis
1115 Pharmacology and Pharmaceutical Sciences
1116 Medical Physiology
Oncology & Carcinogenesis
Publication Status: Published
Online Publication Date: 2021-08-15
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Department of Surgery and Cancer
Faculty of Medicine

This item is licensed under a Creative Commons License Creative Commons